参考文献

[1]吴武华，谷守娜，缪子敬.两性霉素B制剂的研究进展[J].天津药学，2014，26（4）：70-72.

[2]孔旭东，王晓星，陈玥，刘晓.两性霉素B不同制剂的药学特性和临床应用[J].临床药物治疗杂志，2022，20（7）：7-12.

[3]Ullmann AJ，Aguado JM，Arikan-Akdagli S，et al.Diagnosis and management of Aspergillus diseases：executive summary of the 2017 ESCMID-ECMM-ERS guideline[J].Clin Microbiol Infect，2018，24（Suppl 1）：e1-e38.

[4]Tissot F，Agrawal S，Pagano L，et al.ECIL-6 guidelines for the treatment of invasive candidiasis，aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J].Haematologica，2017，102（3）：433-444.

[5]Patterson TF，Thompson GR 3rd，Denning DW，et al.Practice guidelines for the diagnosis and management of aspergillosis：2016 update by the Infectious Diseases Society of America[J].Clin Infect Dis，2016，63（4）：e1-e60.

[6]Pappas PG，Kauffman CA，Andes DR，et al.Clinical practice guideline for the management of candidiasis：2016 update by the Infectious Diseases Society of America[J].Clin Infect Dis，2016，62（4）：e1-e50.

[7]Bellocchio S，Gaziano R，Bozza S，et al.Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4[J].J Antimicrob Chemother，2005，55（2）：214-222.

[8]Simitsopoulou M，Roilides E，Dotis J，et al.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B[J].Antimicrob Agents Chemother，2005，49（4）：1397-1403.

[9]Wingard JR，White MH，Anaissie E，et al.LAmph/ABLC Collaborative Study Group.A randomized，double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia.L Amph/ABLC Collaborative Study Group[J].Clin Infect Dis，2000，31（5）：1155-1163.

[10]李俊.临床药理学[M].6版.北京：人民卫生出版社，2018.

[11]杨宝峰，陈建国.药理学[M].9版.北京：人民卫生出版社，2018.